Abstract

Background and Aim: Norepinephrine is currently the first-line vasopressor for septic shock. We conducted this meta-analysis to examine the outcomes of adult patients with septic shock who received vasopressin instead of norepinephrine.

Methods: We selected studies in adults with septic shock that compared the outcomes of patients treated with vasopressin versus norepinephrine. Cochrane ROB 2.0 and the Joanna Briggs Institute quality assessment tools were used to assess the risk of bias in RCTs and observational studies. Meta-analysis was conducted using RevMan 5.4.

Results: Eight studies were included in this meta-analysis. There were no significant differences in 28-day mortality rates (OR, 1.07; CI, 0.80–1.44) and intensive care unit (ICU) mortality (OR, 0.74; CI, 0.21–2.67) between the two groups. Similarly, length of ICU stay, length of hospital stay, mean arterial pressure at 24 h, urine output at 24 h, and serious adverse events also did not differ significantly. However, the odds of renal replacement therapy (RRT) requirement in the vasopressin group were substantially lower than in the norepinephrine group (OR, 0.68; CI, 0.47–0.98).

Conclusion: There were no differences in mortality, duration of hospitalization, and adverse effects in adults with septic shock across the two groups. However, the patients treated with vasopressin had lower chances of requiring RRT.

Relevance for Patients: Vasopressin use as the first-line vasopressor in septic shock showed a significant reduction in RRT, though there were no significant differences in terms of mortality and other adverse events. Therefore, vasopressin can be considered as a first-line vasopressor in septic shock patients with other risk factors which may contribute to renal failure requiring RRT.

1. Introduction

Septic shock is the leading cause of mortality in intensive care units (ICUs) [1,2]. In 2015, it was estimated that there were more than 230,000 cases of septic shock in the United States which directly caused more than 40,000 deaths per year [3]. Septic shock management revolves around timely source control and hemodynamic resuscitation,
ensuring end-organ perfusion. Crystalloids are used to expand the intravascular volume and catecholamine infusions, that is, norepinephrine, to provide cardiovascular support. Catecholamines, however, may reduce blood flow to end organs despite adequate perfusion pressure [4,5]. Vasopressin is an endogenously released peptide hormone that has been used as an adjunct to catecholamines for patients with septic shock not responding to fluids. Studies have shown that septic shock patients have relative vasopressin deficiency [6,7]. Vasopressin use restores vascular tone and decreases norepinephrine requirements [6,7]. Two small randomized and controlled trials (RCTs) showed that vasopressin improved mean arterial pressure (MAP) and expedited norepinephrine withdrawal [8,9]. Furthermore, vasopressin maintained glomerular filtration rate and creatinine clearance compared with norepinephrine [8,10]. The VASST trial, the largest multicenter, double-blind RCT, compared vasopressin, and norepinephrine in patients with septic shock; no mortality benefit was demonstrated in the trial [11]. In the subsequent VANISH trial, early use of vasopressin compared with norepinephrine did not improve the number of kidney failure-free days [12]. Yet, the trial mentioned that the confidence interval included a potential clinically meaningful benefit for vasopressin and the need for further large-scale trials, highlighting a persistent knowledge gap.

In light of the knowledge gap regarding the benefits of vasopressin in septic shock, we sought to conduct this systematic review and meta-analysis to appraise the available evidence fully and compare the use and benefits of vasopressin compared to norepinephrine in patients with septic shock.

1.1. Objectives

The objectives of the study are as follows:

- To compare mortality and length of stay in patients with septic shock receiving norepinephrine compared to vasopressin
- To compare MAP and urine output in patients with septic shock receiving norepinephrine compared to vasopressin
- To compare serious adverse events and renal replacement therapy (RRT) among patients with septic shock receiving norepinephrine compared to vasopressin.

2. Methods

Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were used for our systematic review [13]. The protocol for review was published in PROSPERO (CRD42021226012) [14].

2.1. Inclusion criteria

2.1.1. Types of studies

We included studies focusing on mortality, clinical improvement, length of hospital stays, adverse effects, mean difference of clinical improvement, and recovery among patients receiving vasopressin compared to norepinephrine for septic shock.

2.1.2. Types of participants

We included all adult patients suffering from septic shock who are more than 18 years of age who received vasopressin or norepinephrine.

2.1.3. Types of Interventions

The treatment arm consists of patients receiving vasopressin for septic shock, while the control arm consists of patients receiving norepinephrine for septic shock.

2.1.4. Types of outcome measures

For our quantitative analysis, mortality, length of stay, MAP, urine output, RRT, and serious adverse effects rates were the outcomes of interest.

2.1.5. Outcomes

We compared mortality, length of stay, MAP, urine output, RRT, and serious adverse effects among septic shock patients receiving vasopressin compared to those receiving norepinephrine.

2.2. Search strategies

PubMed, PubMed Central, Embase, and Scopus were independently searched, and the quality of the studies done in the past decade was evaluated. Finally, we filtered the studies using Covidence and extracted data for quantitative and qualitative synthesis [15]. Any potential conflict was solved by taking the final opinion of another reviewer.

2.2.1. Electronic searches

We have documented the detailed search strategy in Supplementary File 1.

2.3. Data collection and analysis

We extracted the data for quantitative synthesis through Covidence and did the analysis using RevMan5.4 [15,16]. We used a random/fixed effect to pool selected studies based on heterogeneity.

2.3.1. Selection of studies

We have included RCTs, prospective, observational studies, and cohort studies for septic shock, comparing the outcomes of those receiving vasopressin with norepinephrine. We excluded studies in the entire study population in which vasopressin was used for the treatment among the pediatric age group, pregnant women, and shock other than septic shock. In addition, we excluded meta-analyses, reviews, editorials, commentary, and the studies with no data required for quantitative analysis.

2.3.2. Data extraction and management

We evaluated the quality of studies thoroughly and considered only the outcomes in our interest.

2.3.3. Assessment of risk of bias in included studies

We used the Cochrane ROB 2.0 tool to analyze our RCTs (Figure 1) and the Joanna Briggs Institute (JBI) quality assessment...
tools to assess the risk of bias in our prospective and retrospective observational studies (Table 1) [17,18]. We used RevMan 5.4 for creating a summary of biases for RCTs using the Cochrane ROB 2.0 tool.

2.3.4. Assessment of heterogeneity

The I-squared (I²) test was used for the assessment of heterogeneity [22]. We interpreted the I-squared (I²) test done based on the Cochrane Handbook for Systematic Reviews of Interventions [22].

2.3.5. Assessment of reporting biases

Reporting bias was checked by prefixed reporting of the outcome.

2.3.6. Data synthesis

Statistical analysis was performed using RevMan 5.4 software. Odds ratio (OR) was used for outcome estimation with a 95% confidence interval (CI). The fixed/random-effects model was used according to heterogeneities. Mean and standard deviation were formulated based on median and interquartile range. We used mean differences for outcomes such as the length of stay, MAP, and urine output using the mean and standard deviation values obtained from the study [23].

2.3.7. Subgroup analysis and investigation of heterogeneity

We used the random effect model in cases of heterogeneity.

2.3.8. Sensitivity analysis

Non-randomized studies were excluded for sensitivity analysis to find any alterations in the outcomes after removal.

3. Results

A total of 2442 studies were imported after a comprehensive database search. After removing duplicates, the title and abstracts of 2417 studies were screened, followed by the exclusion of 2382 studies. Thirty-five full-text studies were assessed for eligibility, and 27 studies were excluded for definite reasons. Eight studies were included in the narrative summary (Table 2), and seven studies were included in the quantitative analysis. The following is represented in the PRISMA flow diagram (Figure 2).

![Figure 1. Cochrane ROB bias assessment.](image)

### Table 1. JBI bias assessment.

| S. No | JBI checklist for cohort studies                                                                 | Russell et al., 2018 [19] | Hall et al., 2004 [20] | Daley et al., 2013 [21] |
|-------|-----------------------------------------------------------------------------------------------|---------------------------|------------------------|-------------------------|
| 1     | Were the two groups similar and recruited from the same population?                            | Yes                       | Yes                    | Yes                     |
| 2     | Were the exposures measured similarly to assign people to both exposed and unexposed groups?  | Yes                       | Yes                    | Yes                     |
| 3     | Was the exposure measured in a valid and reliable way?                                         | Yes                       | Yes                    | Yes                     |
| 4     | Were confounding factors identified?                                                           | No                        | Yes                    | No                      |
| 5     | Were strategies to deal with confounding factors stated?                                       | No                        | Yes                    | No                      |
| 6     | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | Yes                       | Yes                    | Yes                     |
| 7     | Were the outcomes measured in a valid and reliable way?                                       | Yes                       | Yes                    | Yes                     |
| 8     | Was the follow-up time reported and sufficient to be long enough for outcomes to occur?       | Yes                       | Yes                    | Yes                     |
| 9     | Was follow-up complete, and if not, were the reasons to loss to follow-up described and explored? | Unclear                   | Yes                    | Yes                     |
| 10    | Were strategies to address incomplete follow-up utilized?                                      | No                        | NA                     | NA                      |
| 11    | Was appropriate statistical analysis used?                                                     | Yes                       | Yes                    | Yes                     |
| Overall appraisal |                                                                                  | Include                   | Include               | Include               |

DOI: http://dx.doi.org/10.18053/jctres.08.202203.005
Table 2. Narrative summary of included studies.

| Study ID | Population | Intervention | Comparisons | Outcome |
|----------|------------|--------------|-------------|---------|
| Patel et al., 2002 [8] | Patients experiencing septic shock that required high dose vasopressor support | The starting volume of the vasopressin infusion was 7 ml/h. This corresponded to a vasopressin infusion of 0.01 units/min. The maximum rate of infusion allowed in this study protocol was 56 ml/h of blinded study drug, which corresponded to a vasopressin infusion rate of 0.08 units/min | The starting volume of the norepinephrine infusion was 7 ml/h. This corresponded to a norepinephrine infusion of 0.01 units/min. The maximum rate of infusion allowed in this study protocol was 56 ml/h of blinded study drug, which corresponded to a norepinephrine infusion rate of 0.08 units/min | Mean arterial pressure: Median (q1, q3) |
| T: Baseline 69 (65,72) | Baseline 68 (65,70) mm of Hg |
| C: Baseline 68 (65,70) | Baseline 67 (61,70) mm of Hg |
| Urine output: Mean |
| T: Baseline: 32.5 ml/h After 4 h: 65 ml/h |
| C: Baseline: 25 ml/h After 4 h: 15 ml/h |
| Cardiac index: Median (q1, q3) |
| T: Baseline 4.8 (3.5,5.5), After 4 h: 4.4 (3.1,5.3) |
| C: Baseline 5.0 (3.8, 5.6) After 4 h: 4.0 (3.2, 5.1) |

| Morelli et al., 2009 [24] | Patients with septic shock with mean arterial pressure below 65 mm of Hg despite adequate volume resuscitation | T1: Vasopressin (0.03 units/min) T2: Terlipressin (1.3 μgkg⁻¹ h⁻¹) All three groups received open-label norepinephrine and intravenous hydrocortisone as a continuous infusion | C: Norepinephrine (15 μg/min⁻¹) | ICU mortality |
| T1: 8/15 T2: 7/15 C: 10/15 |
| ICU length of stay (Median, q1, q3) |
| T1: 17 (5,27) T2: 14 (9,25) C: 17 (7, 23) |
| Norepinephrine requirement at 48 h |
| T1: 0.8 μgkg⁻¹ min⁻¹ T2: 0.2 μgkg⁻¹ min⁻¹ C: 1.2 μgkg⁻¹ min⁻¹ |
| Urine output (ml/h) |
| T1: Baseline: 42.3±46.9; 24 h: 42±41.6; 48 h: 43.3±58.7 |
| T2: Baseline: 34.6±31.3; 24 h: 49.2±49.5; 48 h: 46.6±33.3 |
| C: Baseline: 38.6±34.3; 24 h: 66±77; 48 h: 58.6±63.8 |
| Mean arterial pressure |
| T1: Baseline: 72±7 C: 68±10 mm Hg |
| T2: Baseline: 49.2±49.5; 48 h: 46.6±33.3 |
| C: Baseline: 38.6±34.3; 24 h: 66±77; 48 h: 58.6±63.8 |
| Cardiac index |
| T1: Baseline: 53±4; 24 h: 70±3; 48 h: 71±3 mmHg |
| T2: Baseline: 53±4; 24 h: 71±3; 48 h: 71±4 mmHg |
| C: Baseline: 54±3; 24 h: 71±2; 48 h: 71±3 mmHg |
| Heart rate |
| T1: Baseline: 100±22 At 48 h: 93±25 bpm |
| T2: Baseline: 95±16 At 48 h: 71±16 bpm |
| C: Baseline: 97±21 At 48 h: 96±21 bpm |
| Systemic vascular resistance index: |
| T1: Baseline: 41±12 At 48 h: 43±12 ml/beat/m |
| T2: Baseline: 46±13 At 48 h: 50±10 ml/beat/m |
| C: Baseline: 4.0±1.0 At 48 h: 3.9±1.5 ml/beat/m |
| Urine output baseline |
| T1: Baseline: 1420±656 ml C: 1146±700 ml |
| 24h: T: 2049±562 ml C: 1895±1292 ml |
| 48h: T: 3051±1666 ml C: 2644±1060 ml |
| Mean arterial pressure mean, SD |
| Baseline: 72±7 C: 68±10 mm Hg |
| 1 h: T: 74±8 C: 72±5 mm Hg |
| 24 h: T: 81±1 C: 77±6 mm Hg |
| 48 h: T: 78±12 C: 81±9 mm Hg |
| Heart rate mean, SD |
| Baseline: 118±16 C: 109±23 bpm |
| 1 h: T: 105±16 C: 108±22 bpm |

(Contd...)
| Study ID | Population | Intervention | Comparisons | Outcome |
|----------|------------|--------------|-------------|---------|
| Russell et al., 2008 [11] | Patients older than 16 years of age who had septic shock that was resistant to fluids (as defined by lack of response to 500 ml of normal saline or a requirement for vasopressors and low-dose norepinephrine) N=778 (T=396, C=382) | Blinded vasopressin infusion was started at 0.01 U per minute and titrated to a maximum of 0.03 U per minute | Blinded norepinephrine infusion was started at 5 μg per minute and titrated to a maximum of 15 μg per minute | 6 h: T: 100±15 C: 104±22 bpm 48 h: T: 93±21 C: 96±18 bpm Cardiac index mean, SD Baseline: T: 4.6±1.0 C: 4.4±1.4 1 h: T: 3.6±1.1 C: 4.3±1.4 6 h: T: 3.7±0.7 C: 4.3±1.7 48 h: T: 3.7±0.9 C: 3.7±1.6 Mortality ICU T: 2/13 C: 1/10 Acute coronary syndrome T: 1/13 C: 1/10 28-day mortality Randomization: T=144/404 C=154/395 Randomization and infusion: T=140/396 C=150/382 90 day mortality Randomization T=177/400 C=194/391 Randomization and infusion T=172/392 C=188/379 Length of ICU stay median, IQR T (396) =15 (7-29); C (382) =16 (8-32) Length of Hospital stay median, IQR T (396)=27 (13-52), C (382)=26 (15-53) Serious adverse events T=41/396 C=40/382 Acute myocardial infarction T=8/396 C=7/382 Cardiac arrest T=3/396 C=8/382 Life-threatening arrhythmia T=8/396 C=6/382 Acute mesenteric ischemia T=9/396 C=13/382 Hyponatremia T=1/396 C=1/382 Digital ischemia T=8/396 C=2/382 Cerebrovascular accident T=1/396 C=1/382 | Russell et al., 2018 [19] | Patients admitted to Intensive care unit who had two of four SIRS criteria who had suspected or proven infection and who were unresponsive to fluid resuscitation and received infusion of norepinephrine or vasopressin. SPH 1: Before matching T: 165 C: 558 Age: T: 56.1±15.7 C: 60.7±16.2 Male: T: 73.3% C: 61.8% After matching T: 158 C: 158 Age: T: 56.4±15.4 C: 57.1±15.1 Male: T: 72.8% C: 67.1% SPH 2: Before matching T: 525 C: 145 Vasopressin as per local practice Nor epinephrine as per local practice 28 day mortality SPH 1: After matching T: 96/158 C: 73/158 SPH 2: After matching T: 29/93 C: 25/93 |
| Study ID          | Population                                                                 | Intervention                                                                 | Comparisons                                                                 | Outcome                        |
|------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------|
| Gordon et al., 2016 [12] | Double blind, randomized clinical trial                                     | Adult patients (≥16 years) who had sepsis and required vasopressors despite adequate intravenous fluid resuscitation. N=409 | T1=Vasopressin and hydrocortisone T2=Vasopressin and placebo T=Vasopressin with placebo or hydrocortisone Vasopressin (titrated upto 0.06 U/min) as the initial vasopressor infusion. Once maximum infusion rate of vasopressin was reached, either 50 mg of hydrocortisone phosphate or placebo was administered as an intravenous bolus every 6 h for 5 days, every 12 h for 3 days and then once daily for 3 days | C1=Norepinephrine and hydrocortisone C2=Norepinephrine and placebo C=Norepinephrine with or without placebo Norepinephrine titrated upto 12 μg/min as the initial vasopressor infusion. Once maximum infusion rate of norepinephrine was reached, either 50 mg of hydrocortisone phosphate or placebo was administered as an intravenous bolus every 6 days, every 12 h for 3 days and then once daily for 3 days | Hospital Mortality T=68/204 C=60/204 Requirement of RRT T=52/205 C=72/204 ICU length of stay median (IQR) T=7 (3 to 11) C=5 (3 to 15) Hospital length of stay median (IQR) T=16 (7 – 36) days C=16 (8-38) days Serious adverse events T=22/205 C=17/204 Acute coronary syndrome T=7/205 C=4/204 Digital ischemia T=11/205 C=3/204 Mesenteric ischemia T=5/205 C=5/204 Life-threatening arrhythmia T=2/205 C=5/204 Urine output mean, SD Day 1 T (205): 737±3813 ml C (204): 1010±2455 Day 2 T (189): 1521±2204 ml C (198): 1628±1733 Day 7 T (114): 2314±1150 C (99): 1906±1363 28-day mortality T1: 23/44 T2: 28/51 C: 30/46 Hospital stay mean, SD T1 (50): 36±34 days T2 (51): 29±29 days C (49): 36±40 days ICU length of stay mean, SD T1 (50): 14±55 days T2 (51): 20±26 days C (49): 29±40 days Serious adverse events T1: MI T1: 2/50 T2: 2/51 C: 4/49 ARDS T1: 10/50 T2: 12/51 C: 17/49 Atrial arrhythmia T1: 6/50 T2: 6/51 C: 15/49 Acute renal insufficiency T1: 3/50 T2: 3/51 C: 3/49 Venous thromboembolism T1: 7/50 T2: 4/51 C: 1/49 Peripheral vascular necrosis T1: 3/50 T2: 2/51 C: 3/49 Urine output: mean, SD T1 (44): Baseline: 3437±4618, 24 h: 2898±4103 T2 (44): Baseline: 3215±2958 24 h: 4210±6350 C (43): Baseline: 2495±1960 24 h: 2810±2193 Cardiac index mean, SD T1: Baseline: 4.1±1.6; 1 h: 3.5±1.3 T2: 2.8±1.0; 1 h: 2.6±1.2 C: 3.6±1.3; 1 h: 3.3±1.0 MAP T1: Baseline: 63±13.3 mm Hg 1 h: 74.4±11.3 mm Hg T2: Baseline: 58.7±9.5 mm Hg 1 h: 70.5±11.6 mm Hg C: Baseline: 56.8±8.5 mm Hg 1 h: 72.9±8.9 mm Hg |
| Hall et al., 2004 [20] | Retrospective cohort single center study                                     | Critically ill patients who were receiving continuous intravenous infusion of vasopressin, norepinephrine and dopamine N=50, T1=50, T2=51 and C=49 | T1: Fixed dosage of intravenous vasopressin 0.04 U/min T2: Titrated intravenous infusion of dopamine (6.7±5.5 μg/kg/min) | C: Titrated intravenous infusion of norepinephrine (0.28±0. μg/kg/min) | 28-day mortality T1: 23/44 T2: 28/51 C: 30/46 Hospital stay mean, SD T1 (50): 36±34 days T2 (51): 29±29 days C (49): 36±40 days ICU length of stay mean, SD T1 (50): 14±55 days T2 (51): 20±26 days C (49): 29±40 days Serious adverse events T1: MI T1: 2/50 T2: 2/51 C: 4/49 ARDS T1: 10/50 T2: 12/51 C: 17/49 Atrial arrhythmia T1: 6/50 T2: 6/51 C: 15/49 Acute renal insufficiency T1: 3/50 T2: 3/51 C: 3/49 Venous thromboembolism T1: 7/50 T2: 4/51 C: 1/49 Peripheral vascular necrosis T1: 3/50 T2: 2/51 C: 3/49 Urine output: mean, SD T1 (44): Baseline: 3437±4618, 24 h: 2898±4103 T2 (44): Baseline: 3215±2958 24 h: 4210±6350 C (43): Baseline: 2495±1960 24 h: 2810±2193 Cardiac index mean, SD T1: Baseline: 4.1±1.6; 1 h: 3.5±1.3 T2: 2.8±1.0; 1 h: 2.6±1.2 C: 3.6±1.3; 1 h: 3.3±1.0 MAP T1: Baseline: 63±13.3 mm Hg 1 h: 74.4±11.3 mm Hg T2: Baseline: 58.7±9.5 mm Hg 1 h: 70.5±11.6 mm Hg C: Baseline: 56.8±8.5 mm Hg 1 h: 72.9±8.9 mm Hg |
Table 2. (Continued).

| Study ID      | Population                                      | Intervention                                      | Comparisons                                      | Outcome                                      |
|---------------|-------------------------------------------------|--------------------------------------------------|-------------------------------------------------|----------------------------------------------|
| Daley et al., 2013 [21] | Patients with septic shock with mean arterial pressure less than 65 mm Hg. N=130 T=65 C=65 | Administration of vasopressin 1 h after the onset of septic shock | Administration of norepinephrine 1 h after the onset of septic shock | Mortality T=29/65 C=32/65 |
|               | Male T=52.3%, C=53.8%                           |                                                  |                                                  | Length of hospital stay (Median, Interquartile range) T=15 (8-34) C=15 (7-31) |
|               | Female T=47.7%, C=46.2%                         |                                                  |                                                  | ICU length of stay: Median, Interquartile range T=7 (4-24) C=7 (3-15) |
|               | Age mean (SD) T=61 (17.7) C=56 (17.7)           |                                                  |                                                  | Requirement of renal replacement therapy T=19/65 C=21/65 |
|               |                                                  |                                                  |                                                  | MAP mean, SD (mm Hg) T: Baseline: 57.3 (5.9), 0-6 h: 75.0 (9.6); 12-24 h: 71.7 (10.3) C: Baseline: 56.8 (6.4) 0-6 h: 76 (8.2); 12-24 h: 73.4 (11.1) |
|               |                                                  |                                                  |                                                  | Urine output mean, SD (ml/kg/h) T: 0-6 h: 0.84 (1) 6-12 h: 0.72 (0.9) 12-24 h: 0.77 (0.9) C: 0-6 h: 0.63 (1) 6-12 h: 0.66 (0.8) 12-24 h: 0.51 (0.6) |

3.1. Narrative summary

Three included studies were retrospective and cohort studies [19-21] and five were randomized and controlled trials [8,10-12,24].

Patel et al. randomized patients to vasopressin to norepinephrine infusion for 4 h [8]. In the study, vasopressin decreased the catecholamine use in septic shock and achieved significantly higher urine output and creatinine clearance than norepinephrine. However, since Patel et al. were a short duration study, the outcomes were not reported beyond 4 h, and it could not be included in the quantitative synthesis.

Lauzier et al. randomized patients to high-dose vasopressin or norepinephrine in early septic shock [10]. Vasopressin in the
high dose (0.2U/min) could not attain Map in all the patients in the study and required additional epinephrine. However, the patients achieved less modified sofa in the vasopressin arm than norepinephrine arm at 48 h.

Russell et al. (VASST) were the largest RCT with 778 patients, which randomized patients to vasopressin or norepinephrine in septic shock [11]. The primary endpoint of the study was death at 28 days. There was no difference in mortality at 28 days and severe adverse effects in both arms. However, in the patients with less severe septic shock (those who required NE <15 µg/min), vasopressin provided a mortality benefit compared to norepinephrine. Gordon et al. (VANISH trial) were conducted to study the renal effects of vasopressin versus norepinephrine in patients with septic shock [12]. The primary endpoint was the number of kidney-free days. Vasopressin did not increase the number of kidney-free days in septic shock compared to norepinephrine.

The TERLIVAP study (Morelli et al.) was a randomized control trial with three arms: A continuous terlipressin arm, a continuous vasopressin arm, and a fixed-dose norepinephrine arm [24]. The primary endpoint was the additional requirement of norepinephrine. Terlipressin required lower norepinephrine as compared to the vasopressin arm. There was no difference in hemodynamic differences achieved by vasopressin, norepinephrine, and terlipressin.

3.2. Quantitative analysis

A total of seven studies were included in the meta-analysis (four RCTs and three cohorts).

3.2.1. Mortality outcome

Five studies reported 28-day/hospital mortality. Pooling the data using random-effect model, there was no difference in odds of mortality between vasopressin and norepinephrine group among septic shock patients (OR, 1.07; 95% CI, 0.80–1.44; n=1929; I²=51%). Similarly, two studies reported ICU mortality outcome which was not different across two groups (OR, 0.74; 95% CI, 0.21–2.67; n=53; I²=0%) (Figure 3). Further, no significant differences were seen while analyzing the 28-day mortality outcome after excluding non-randomized studies (Supplementary File 2, Figure 1).

3.2.2. Length of Stay

Length of ICU stays outcome was reported by five studies. Pooling of results using the mean difference in length of ICU stay in days showed some reduction in length in the vasopressin group; however, it did not reach the level of significance (MD, −0.49; 95% CI, −3.12–2.14; n=1415; I²=0%) (Figure 4). Further, no significant differences were seen while analyzing for ICU-LOS and LOHS after excluding non-randomized studies (Supplementary File 2, Figure 2).

3.2.3. MAP

Pooling data for MAP (mmHg) showed no significant difference in mean of baseline MAP (MD, 0.08; 95% CI, −1.51–1.66; n=183; I²=0%); MAP at 24 h (MD, −0.88; 95% CI, −2.47–0.72; n=183; I²=3%); and MAP at 48 h (MD, −0.18; 95% CI, −2.26–1.91; n=53; I²=0%) (Figure 5).

3.2.4. Urine output

There was no significant difference in urine output in terms of mean of baseline urine output (MD, 10.91; 95% CI, −6.65–28.46; n=140; I²=0%); urine output at 24 h (MD, −7.47; 95% CI, −25.46–10.52; n=549; I²=0%); and urine output at 48 h (MD, −3.55; 95% CI, −18.21–11.12; n=440; I²=0%) (Figure 6). Further, no significant differences were seen while analyzing for urine output after excluding non-randomized studies (Supplementary File 2, Figure 3).

3.2.5. Serious adverse effect

Three studies reported serious adverse events. Pooling of the data showed no significant differences in its occurrence across two

| Subgroup | Vasoressin | Norepinephrine | Total | Total | M.H. Random | 95% CI | Odds Ratio | Odds Ratio |
|----------|------------|---------------|-------|-------|-------------|--------|------------|------------|
| Hospital mortality | 2 | 1 | 3 | 0.58 | 0 | 0.05 | 0.01 | 0.1 | 1.09 | 1.64 | 1.1210 | 0.0508 | 10.37 | 0.05 |

Figure 3. Forest plot comparing mortality outcome across vasopressin and norepinephrine in septic shock patients.

DOI: http://dx.doi.org/10.18053/jctres.08.202203.005
groups (OR, 1.01; 95% CI, 0.71–1.43; \( n = 1286 \); \( I^2 = 0\% \)) (Figure 7).

3.2.6. RRT

Pooling data from two studies reporting requirement of RRT, the odds for requirement of RRT in vasopressin group were lowered significantly (OR, 0.68; 95% CI, 0.47–0.98; \( n = 539 \); \( I^2 = 0\% \)) (Figure 8).

4. Discussion

We analyzed eight studies in our study. When both medications were compared, neither showed survival benefit over the other. Furthermore, no statistical difference was found between norepinephrine and vasopressin in terms of length of ICU stay, MAP, severe adverse effects, and urine output. Norepinephrine was the first-choice vasopressor for managing hypotension in septic shock. In contrast, vasopressin has been used as one of the first add-on vasopressors to norepinephrine to attain the target MAP or decrease the norepinephrine dosage [25]. Our study found no significant difference between hospital mortality and 28-day mortality among patients treated with either medication. This finding is consistent with other meta-analyses, which have also compared the mortality outcome [26,27]. Similarly, there was no significant difference in the length of ICU stay among the patients. A previous meta-analysis had also reached a similar conclusion [28].

Septic shock is a state of relative vasopressin deficiency attributed to impaired baroreceptor-mediated vasopressin secretion [29]. However, all the clinical implications of the relative deficiency state are not known. A short-term study has shown that the microcirculation effects of vasopressin in patients are dependent on the baseline norepinephrine dose [30]. Regarding the hemodynamic parameters, many hemodynamic parameters were not reported in the studies; however, they were reported with inconsistent time duration. We compared the effect of vasopressin versus norepinephrine on MAP, on which a significant difference could not be found. The previous meta-analysis has reported multiple hemodynamic parameters and MAP, such as heart rate, cardiac index, systemic vascular resistance index, and oxygen consumption, which have no significant differences [26]. The study found no significant difference in the occurrence of major side effects. While vasopressin may increase the incidence of digital ischemia, prior meta-analyses have shown no increase in the incidence of major adverse effects [28,31,32].

DOI: http://dx.doi.org/10.18053/jctres.08.202203.005

Figure 4. Forest plot comparing the length of intensive care unit stay and hospital stay across vasopressin and norepinephrine in septic shock patients.

Figure 5. Forest plot comparing mean arterial pressure across vasopressin and norepinephrine in septic shock patients.
Patel et al. have shown that vasopressin increases urine output and decreases serum creatinine compared to norepinephrine in the early hours of administration [8]. However, there seems to be no difference in kidney failure-free days in patients treated with vasopressin than norepinephrine. Although we did not find any significant difference in urine output in our study, there were lower odds of RRT with vasopressin. Our findings of the decreased requirement for RRT align with the findings of prior clinical studies that have found improvement in glomerular filtration rate and creatinine clearance in the vasopressin group compared to norepinephrine [8,10]. Further studies are necessary to evaluate the implications of possible renal benefits seen with vasopressin compared to norepinephrine.

4.1. Limitations

Our meta-analysis has several limitations, including the small number of available studies and the heterogeneity of study designs and demographics. Included studies have their inherent limitations. The included studies have been conducted from 2002 to 2018 and represent a contemporary cohort of septic shock patients. Treatment protocol, formulations, and drug dosage are comparable and offer granularity of data in assessing individual influence. The presence of organ dysfunction and comorbidities could have influenced the clinical outcomes [33]. We could only report adverse effects and the need for RRT based on a few studies. We could not report various other parameters of interest as there was wide variation in reporting among studies. Furthermore, we have only included studies published in English, which could have excluded studies published in other languages. Further studies are warranted to uncover the pathophysiology of vasopressin in septic shock and its potential role in therapeutics.

5. Conclusion

This comprehensive meta-analysis reports no mortality benefit when comparing vasopressin to norepinephrine in septic shock patients. Yet, the need for RRT was significantly lower in the vasopressin group. In addition, we found no difference in adverse effects.

Figure 6. Forest plot comparing urine output (ml/h) across vasopressin and norepinephrine in septic shock patients.

Figure 7. Forest plot comparing SAE across vasopressin and norepinephrine in septic shock patients.

Figure 8. Forest plot comparing requirement of renal replacement therapy across vasopressin and norepinephrine in septic shock patients.
events and duration of hospitalization in septic shock patients receiving vasopressin compared to norepinephrine. Therefore, further large-scale randomized clinical trials are required to uncover the renal benefit of vasopressin in septic shock.

Conflict of Interest

The authors declare that they have no competing interests.

References

[1] Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current Epidemiology of Septic Shock: The CUB-Réa Network. Am J Respir Crit Care Med 2003;168:165-72.

[2] Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Mrous PS. Epidemiology of Severe Sepsis in the United States: Analysis of Incidence, Outcome, and Associated Costs of Care. Crit Care Med 2001;29:1303-10.

[3] Seymour CW, Rosengart MR. Septic Shock: Advances in Diagnosis and Treatment. JAMA 2015;314:708-17.

[4] Bomezon L, Rosendorff C. Renovascular Resistance and Noradrenaline. Am J Physiol 1975;229:1649-53.

[5] Hayes MA, Timmins AC, Yau E, Palazzo M, Hinds CJ, Watson D. Elevation of Systemic Oxygen Delivery in the Treatment of Critically Ill Patients. N Engl J Med 1994;330:1717-22.

[6] Landry DW, Oliver JA. The Pathogenesis of Vasodilatory Shock. N Engl J Med 2001;345:588-95.

[7] Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of Vasopressin Relevant to Management of Septic Shock. Chest 2001;120:989-1002.

[8] Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial Effects of Short-term Vasopressin Infusion during Severe Septic Shock. Anesthesiology 2002;96:576-82.

[9] Malay MB, Ashton RC, Landry DW, Townsend RN. Low-Dose Vasopressin in the Treatment of Vasodilatory Septic Shock. J Trauma Acute Care Surg 1999;47:699-703.

[10] Lauzier F, Lévy B, Lamarre P, Lesur O. Vasopressin or Norepinephrine in Early Hyperdynamic Septic Shock: A Randomized Clinical Trial. Intensive Care Med 2006;32:1782-9.

[11] Russell JA, Walley KR. Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin Versus Norepinephrine Infusion in Patients with Septic Shock. N Engl J Med 2008;358:877-87.

[12] Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients with Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016;316:509-18.

[13] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-analyses of Studies that Evaluate Healthcare Interventions: Explanation and Elaboration. BMJ 2009;339:b2700.

[14] Shrestha D, Budhathoki P, Gaire S, Pokharel N, Maharjan S, Sedhai Y, et al. Vasopressin vs Nor-adrenaline in septic shock: A Systematic Review and Meta-analysis. PROSPERO; 2021. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=226012 [Last accessed on 2021 Apr 24].

[15] How Can I Cite Covidence? Available from: https://www.support.covidence.org/help/how-can-i-cite-covidence [Last accessed on 2021 Jan 26].

[16] RevMan for Non-cochrane Reviews, Cochrane Training. Available from: https://www.training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-non-cochrane-reviews [Last accessed on 2021 Jan 26].

[17] Sterne JA, Savović J, Page MJ, Elbers RS, Boutron I, et al. RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials. BMJ 2019;366:4898.

[18] Critical-appraisal-tools-critical Appraisal Tools, Joanna Briggs Institute. Available from: https://www.joannabriggs.org/critical-appraisal-tools [Last accessed on 2020 Dec 18].

[19] Russell JA, Wellman H, Walley KR. Vasopressin Versus Norepinephrine in Septic Shock: A Propensity Score Matched Efficiency Retrospective Cohort Study in the VAST Coordination Center Hospital. J Intensive Care 2018;6:73.

[20] Hall LG, Oyen LJ, Taner CB, Cullinane DC, Baird TK, Cha SS, et al. Fixed-dose Vasopressin Compared with Titrated Dopamine and Norepinephrine as Initial Vasopressor Therapy for Septic Shock. Pharmacotherapy 2004;24:1002-12.

[21] Daley MJ, Lat I, Mieure KD, Jennings HR, Hall JB, Kress JP. Una Comparación de la Monoterapia Inicial de Norepinefrina y Vasopresina Para Resucitación De Choque Séptico. Ann Pharmacother 2013;47:301-10.

[22] Conflicting and Measuring Heterogeneity. Available from: https://www.handbook-5-1.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm [Last accessed on 2020 Dec 18].

[23] Mean Variance Estimation. Available from: https://www.web.archive.org/web/20181224162602/http://www.comp.hkbu.edu.hk/~xwan/median2mean.html [Last accessed on 2020 Dec 19].

[24] Morelli A, Ertmer C, Rebberg S, Lange M, Orecchioni A, Cecchini V, et al. Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock (TERLIVAP): A Randomized, Controlled Pilot Study. Crit Care 2009;13:R130.

[25] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017;45:486-552.

[26] Zhou FH, Song Q. Clinical Trials Comparing Norepinephrine with Vasopressin in Patients with Septic Shock.
Shock: A Meta-analysis. Mil Med Res 2014;1:6.

[27] Nagendran M, Maruthappu M, Gordon AC, Gurusamy KS. Comparative Safety and Efficacy of Vasopressors for Mortality in Septic Shock: A Network Meta-analysis. J Intens Care Soc 2016;17:136-45.

[28] Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-analysis. PLoS One 2015;10:e0129305.

[29] Buijk SE, Bruining HA, Oliver JA, Landry DW. Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock. Circulation 1998;98:187.

[30] Nascente AP, Freitas FG, Bakker J, Bafi AT, Ladeira RT, Azevedo LC, et al. Microcirculation Improvement after Short-term Infusion of Vasopressin in Septic Shock is Dependent on Noradrenaline. Clinics 2017;72:750-7.

[31] Yao R, Xia D, Wang L, Wu G, Zhu Y, Zhao H, et al. Clinical Efficiency of Vasopressin or its Analogs in Comparison with Catecholamines Alone on Patients With Septic Shock: A Systematic Review and Meta-analysis. Front Pharmacol 2020;11:563.

[32] Serpa Neto A, Nassar AP, Cardoso SO, Manetta JA, Pereira VG, Espósito DC, et al. Vasopressin and Terlipressin in adult Vasodilatory Shock: A Systematic Review and Meta-analysis of Nine Randomized Controlled Trials. Crit Care 2012;16:R154.

[33] Ketcham SW, Sedhai YR, Miller HC, Bolig TC, Ludwig A, Co I, et al. Causes and Characteristics of Death in Patients with Acute Hypoxemic Respiratory Failure and Acute Respiratory Distress Syndrome: A Retrospective Cohort Study. Crit Care 2020;24:391.

Publisher’s note

Whioce Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

DOI: http://dx.doi.org/10.18053/jctres.08.202203.005
Supplementary: Vasopressin versus norepinephrine as the first-line vasopressor in septic shock: A systematic review and meta-analysis

Supplementary File 1. Electronic search details

**Embase**

Search: ("vasopressin"/exp OR vasopressin) AND ("nor adrenaline" OR "nor epinephrine") AND ("septic shock"/exp OR "septic shock" OR (septic AND ("shock"/exp OR shock)) OR "sepsis"/exp OR sepsis)

Link: https://www.embase.com/#advancedSearch/resultspage/history.13/page.1/25.items/orderby.date/source.
Total hits: 4

**PubMed**

Search: ((Vasopressin) AND (Nor-adrenaline or Nor-epinephrine)) AND (Septic shock or sepsis)

Link: https://pubmed.ncbi.nlm.nih.gov/?term=%28%22Vasopressin%22+AND+%22Nor-adrenaline+or+Nor-epinephrine%22%29+AND+%22Septic+shock+or+sepsis%22%29&sort=date
Total hits: 354

**PubMed Central**

Search: ((Vasopressin) AND (Nor-adrenaline or Nor-epinephrine)) AND (Septic shock or sepsis)

Link: https://www.ncbi.nlm.nih.gov/pmc/?term=((Vasopressin)+AND+(Nor-adrenaline+or+Nor-epinephrine))+AND+(Septic+shock+or+sepsis)
Total hits: 2363

**Cochrane Library**

No findings

**Scopus**

Search: “Vasopressin” AND (“Nor-adrenaline” or “Nor-epinephrine”) AND (“Septic shock” or “sepsis”)

Link:https://www.scopus.com/results/results.uri?numberOfFields=0&src=s&clickedL=ink=&edit=&editSaveSearch=&origin=searchbasic&authorTab=&affiliationTab=&advancedTab=&scint=1&menu=search&tablin=&searchterm1=+%22Vasopressin%22+AND+%22Nor-adrenaline%22+or+%22Nor-epinephrine%22%29+AND+%22Septic+shock%22+or+%22sepsis%22%29&field1=TITLE_ABS_KEY&dateType=Publication_Date_Type&yearFrom=Before+1960&yearTo=Present&loadDate=7&doctype=All&resetFormLink=&st1=+%22Vasopressin%22+AND+%22Nor-adrenaline%22+or+%22Nor-epinephrine%22%29+AND+%22Septic+shock%22+or+%22sepsis%22%29&sid=98b53e3b530215da51c640cd717903d4&txGid=c6eb180e933f7eea68f5605edc8353d&sort=plf-f&originationType=b&rr=

Hits: 1
Supplementary File 2. Additional analysis

1. Morality
   Sensitivity analysis for 28-day mortality outcome conducted by excluding non-randomized studies (Hall et al., 2004, and Russell et al., 2018) also could not show significant differences across two groups (OR, 0.95; 95% CI, 0.76–1.18; n=1337; I²=0%) (Figure 1).

   ![Figure 1. Forest plot showing mortality outcome after excluding non-randomized study.](image1)

2. LOS
   Excluding non-randomized study (Hall et al.) also could not make significant difference in overall ICU (MD, −0.19; 95% CI, −1.30–0.91; n=1346; I²=32%), and length of hospital stay (MD, −0.51; 95% CI, −3.18–2.17; n=1316; I²=0%) (Figure 2).

   ![Figure 2. Forest plot showing LOS outcome after excluding non-randomized study.](image2)
3. **Urine output**

Excluding non-randomized study (Hall *et al.*.) also could not make significant difference in baseline urine output (MD, 8.42; 95% CI, −9.88–26.73; *n*=53; I²=0%), and 24-h urine output MD, −8.68; 95% CI, −27.62–10.27; *n*=462; I²=0%) (**Figure 3**).

**Figure 3.** Forest plot showing urine output after excluding non-randomized study.